Colon cancer enzyme
One
in eight cancers in Germany affects the colon or the rectum. In 2020,
this affected 26,392 women and 32,120 men.
Colon
cancer affects one in 20 women and one in 17 men. The risk of
developing colon cancer increases with age. More than half of
colorectal cancer patients are older than 70 years. Among the under
55-year-olds the rate is only about 10 percent. The mean age of onset
is 76 years for women and 72 years for men, and is therefore
comparatively high.
After
the incidence rate rose briefly, the age-standardized incidence rates
declined from around 2003. A trend that has even intensified
recently. The age-standardized death rates for both sexes have even
declined by around 20 percent in the past ten years. With colon
cancer, women have a relative chance of survival of 63 percent within
five years, while it is only one percent less for men, at 62
percent.
The
colon cancer enzyme No. 6 slows down the growth and spread of cancer
cells in the organism.
Cancer
cells use various strategies to bypass the body's natural immune
defenses. To wander to other parts of the body undetected, they
camouflage themselves with a cover made of an endogenous substance.
Colon cancer enzyme , however, can recognize these cells and destroy
them. This effectively prevents metastases.
Cancer
cells can also form structures that the immune system classifies as
harmful and destroys them. As a result, living cancer cells remain
undetected and can multiply freely. This deception is also undermined
by the colon cancer enzyme No. 6, which splits these camouflaging
structures.
https://cancer-enzyme.com/product_info.php?info=p13_colon-cancer-enzyme.html
Keine Kommentare:
Kommentar veröffentlichen